Biopharm stock soars on FDA ruling
Æterna Zentaris (TSX: T.AEZ) shares shot up 30% to $1.45 on Wednesday as the global biopharmaceutical firm focused on endocrine therapy and oncology announced that Keryx Biopharmaceuticals, its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Pharma firm surges on FDA news
Shares of Angiotech Pharmaceuticals (TSX: T.ANP) surged more than 48% to $2.87 Monday, as the Vancouver-based company announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Option Inferior Vena Cava Filter in the United States.
BioCryst adding to influenza stockpiles: Ticker Trax Update
In a conference call this morning, BioCryst Pharmaceuticals said its influenza treatment, administered intravenously, is in the midst of a U.S. government review for emergency use.
Don’t chase swine flu stocks; BioCryst (BCRX) still undervalued, says Calandra
Despite its recent share price surge, Thom Calandra thinks BioCryst Pharmaceuticals (NASDAQ: BCRX) is still undervalued and doesn’t think anyone in for a quick trade should be selling the stock. He believes it’s a way of preparing for a scenario that at some point will arise in the world – it is almost inevitable that a pandemic will come.
BioCryst Pharmaceuticals down Wednesday after 140% surge
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) gave back some of this week’s impressive gains Wednesday, down 18.6% to $3.40, while news of the swine flu continued to dominate headlines.
Micromet soars on new cancer treatment
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced publication of a Phase 1 clinical study.
